ation * CAAT enhancer binding proteins * differentiationtranscription factor During the period of rapid cell growth which follows a twothirds partial hepatectomy, the liver is able to compensate for the acute loss of two-thirds of its mass to maintain serum glucose levels and many of its differentiation-specific functions. However certain hepatic transcription factors, C/ EBPa and (3, which are important for establishment and maintenance of the differentiated state, have been shown to be antagonistic to cellular proliferation. To study the interplay between differentiation and cell growth in the liver regeneration model of hepatocyte proliferation, we characterized the expression of C/EBPa and (3 transcription factors throughout the temporal course of liver regeneration. As determined by immunoblot, the level of C/EBPa decreases more than twofold during the mid to late G1 and S phase (8-24 h after hepatectomy) coordinately with a threefold increase in expression of C/EBPI3. Renormalization of the levels of these proteins occurs after the major proliferative phase. This inverse regulation of C/EBPa and (3 results in up to a sevenfold increase in the (3/a DNA binding ratio between 3 and 24 h after hepatectomy that may have an important impact on target gene regulation.
Introduction
The liver is one of the few normally quiescent tissues in the adult body that has the capacity to regenerate. In the rat, after a 70% partial hepatectomy virtually all remnant liver cells reenter the cell cycle (1) (2) (3) . The first round of DNA synthesis occurs at 12-16 h and the liver regains its original mass within 7-10 d. Multiple factors, including circulating hormones, growth factors, and nervous input, appear to participate in the growth response. Although the majority of hepatocytes undergo a proliferative response, the liver retains and even enhances its ability to perform most of the cellular processes required to maintain homeostasis as reflected by its continued synthesis of liver-specific factors including albumin, coagulation factors, and bile (1) and its ability to maintain normal serum glucose levels. In this regard, gluconeogenic genes glucose-6-phosphatase (G6Pase) ' and phosphoenolpyruvate carboxykinase (PEPCK) are induced rapidly in the regenerating liver within minutes of partial hepatectomy, thereby preventing the fall of serum glucose that would accompany the acute loss of liver mass (4, 5) . Similarly, at the time of birth when the liver is rapidly proliferating, serum glucose must be established and maintained by the neonatal liver. To accomplish this, we hypothesize that during rapid proliferation the hepatocyte must continue to express transcription factors that are important for the regulation of liver-specific genes.
The regenerating hepatocyte enters proliferation accompanied by the expression of immediate-early (protein synthesis independent) genes during the GO to G1 transition (4, (6) (7) (8) (9) (10) (11) (12) . Immediate-early genes are transactivated by preexisting transcription factors that are inactive in the normal liver but are activated within minutes of the partial hepatectomy after posttranslational modifications. Two such preexisting transcription factors that are activated in the regenerating liver in the absence of de novo protein synthesis include posthepatectomy factor/ nuclear factor KB (PHF/NF-KB, a p65/pSO KB site DNA binding complex (13, 14) , and Stat3 (15) , an IL-6 and EGF inducible factor. Immediate-early genes themselves encode many transcription factors, growth factors, and signal transduction molecules. Recent studies indicate that many transcription factors (e.g., CAAT enhancer binding protein [C/EBP], NF-KBB) interact to enhance transcription of target genes (16) (17) (18) , and it seems likely that growth-induced transcription factors and constitutive hepatic transcription factors interact to regulate liver growth and function during liver regeneration.
The mechanisms that result in the maintenance of differentiation-specific cellular processes in the liver during this period of rapid cell growth are not well understood. The hepatocyte nuclear factor (HNF) class of transcription factors, including HNF1,4, and 3a,fi, y which are responsible for regulation of many liver-specific genes, continues to be expressed at normal levels during liver regeneration (19, 20) . C/EBPs are also important transcription factors in the differentiated liver. C/EBPa and /3 are members of a family of bZIP transcription factors that have been implicated in the establishment and maintenance of cellular differentiation (21) (22) (23) . C/EBPa and /3 are highly expressed in liver, and their expression increases at the time of birth when the liver is still rapidly proliferating (24, 25) . C/ EBPa and /3 are able to activate the transcription of several liver-specific genes associated with the differentiated state including albumin (26) , alpha-l-antitrypsin (27) , and PEPCK (28) . Although C/EBPa is expressed in developing proliferating hepatocytes, in adipocytes C/EBPa may have an antiproliferative function, based on the observation that premature C/ EBPa expression in preadipocytes results in cessation of cell growth (29) (30) (31) (32) . C/EBP,/ has been shown to have a similar antiproliferative effect in some hepatoma cell lines (33) .
Because of the need to maintain differentiated function during liver regeneration and the proposed negative impact of C/ EBPs on proliferation, investigators have attempted to quantitate the level of C/EBPs in liver regeneration. Results are conflicting, with some investigators finding profound decreases in C/EBPa mRNA and others seeing less effect (4, 19, (34) (35) (36) . However, it is the level of active protein that is the most critical in determining the impact of C/EBP isoforms on gene expression. Measurements of C/EBP protein levels in liver regeneration have shown substantial variability and lack of consistency within and between studies allowing no conclusions to be drawn ( 19, 36) . None of these studies have examined the full temporal course of protein expression and DNA binding activity, and more important, they do not assess in situ expression of the C/ EBPs to see if zonal expression is observed in proliferating hepatocytes. If zonal expression were observed, then one could hypothesize that hepatocytes maintain differentiated function only at specific times in the cell cycle. Based on earlier studies (34), we hypothesized that C/EBP proteins would be expressed throughout the period of liver regeneration after partial hepatectomy. Here, we demonstrate that C/EBPa and /3 proteins are present throughout a 7-d period after partial hepatectomy, but the ratio of C/EBP/3 to a increases during the first 24 h. Using in situ immunohistochemistry analyses, we show that the expression of both C/EBPa and /3 is compatible with immediateearly protein expression and progression of hepatocytes into S phase of the cell cycle.
Methods
Animals. For partial hepatectomy, female Fischer rats ( 160-200 grams) were ether anesthetized and subjected to midventral laparotomy with -70% liver resection (left lateral and median lobes) (37 Antibodies. Antibodies used were: a-C/EBPa "C103" (raised against intact polypeptide corresponding to C/EBPa open reading frame); a-C/EBPa "a-14" (raised against amino acids 253-265); a-C/EBPa "a-N" (raised against NH2-terminal portion of C/EBPa polypeptide); a-C/EBPa "a-C104, a-C106" (raised against internal peptide upstream of a-14); a-C/EBP/3 (raised against amino acids 258-276); a-proliferating cell nuclear antigen (a-PCNA; Santa Cruz Biotechnology, Santa Cruz, CA); a-c-Jun (27) ; a-rat albumin (Cappel Laboratories, Cochranville, PA); a-bromodeoxyuridine (a-BrdU;
Boehringer-Mannheim, Indianapolis, IN). All C/EBPa and P antibodies were gifts from Steven McKnight with the exception of a-C/EBP "14AA" (Santa Cruz Biotechnology) and a-C/EBP/3 "C-19" (Santa Cruz Biotechnology). 14AA and C-19 were raised against the same amino acids as a-C/EBPa "a-14" and a-C/EBPf3, respectively; a-Cl EBPa "a-14" [ Fig. 1 A] ; a-C/EBPa "14AA" [Figs. 1 C, 3 A, right panel, and C]; equal mixture of a-C/EBPa "a-N", a-C/EBPa "C104", a-C/EBPa"C106" [ Fig. 3 (40) . C/EBPa protein expression was detected using either a-C/EBPa "a-14" (gift from Steven McKnight) (Fig. 1 A) or a-C/EBPa "14 AA" (Santa Cruz Biotechnology) (Fig. 1 C) . Both antibodies were raised against amino acids 253-265 of the C/EBPa polypeptide. C/EBP/3 protein expression was detected using a-C/EBP/3 (described above). Primary antibodies were diluted 1:1,000 and incubated with the membrane for 1 h at room temperature. Horseradish peroxidase-linked secondary antibody was then added at a dilution of 1:10,000 for 1 h. Densitometric scanning of a separate Coomassie-stained gel was used to normalize amounts of protein loaded in each lane.
Gel mobility shift assays (EMSA). Binding reactions were performed essentially as described (41) . All experiments were performed using an excess of probe. 5 (Fig. 3 , A, right panel, and C); equal mixture of a-C/EBPa "a-N" (raised against NH2-terminal portion of C/EBPa polypeptide), a-C/EBPa "C104," "C106" (raised against internal peptide upstream of "a-14") (gift of Steven McKnight) ( Fig. 3 A, left panel); a-C/ EBP/3 "C-19" (Santa Cruz Biotechnology) (raised against amino acids 258-276) (Fig. 3 , B, right panel, and C). Liver perfusion. Hepatectomized rats were reanesthetized and ventral laparotomy was performed. Rats whose livers were used for BrdU incorporation experiments received an intraperitoneal injection of BrdU C/EBP Protein Expression in Liver Regeneration (Sigma Immunochemicals, St. Louis, MO) at a dose of 50 mg/kg 1 h before killing (42) . Normal liver was prepared by subjecting rats directly to laparotomy and subsequent perfusion. The portal vein was cannulated using a 16-gauge angiocath followed by a 5-min PBS perfusion, pH 7.3. Freshly prepared 2% paraformaldehyde/PBS, pH 7.2, (40C) was then perfused for 10 min at a rate of 15 ml/min. The fixed liver was removed and cut into 5-mm slices with a razor blade followed by a 1-h postfixation in 2% paraformaldehyde/PBS (40C). The liver slices were paraffin embedded in an automated tissue processor. 5-pm tissue sections were cut on a microtome and adhered to poly-X-lysinecoated glass slides. The slides were dried overnight at 37TC.
Immunohistochemistry. Immunohistochemistry for detection of C/ EBPa, /3, c-Jun, and albumin was performed essentially as described (43) . Tissue sections were rehydrated in xylene followed by graded alcohols. The Vectastain Elite ABC avidin biotin horseradish peroxidase detection system (Vector Labs, Inc., Burlingame, CA) was used according to the manufacturer's instructions with the following modifications. After the blocking step in 3% goat serum in PBS, avidin and biotin blocking steps were performed using the Vector Laboratories Avidin-Biotin blocking kit. Antibodies used include a-C/EBPa "C103" (raised against intact polypeptide corresponding to C/EBPa open reading frame) (gift from Steven McKnight); a-C/EBP/3; a-cJun (27) ; a-rat albumin (Cappel Laboratories); a-PCNA (Santa Cruz Biotechnology); and a-BrdU (Boehringer-Mannheim Sections were then washed in PBS for 10 min followed by two 5-min washes in 0.25% Triton X-100/PBS. ABC reagent and substrate incubations were performed according to the manufacturer's instructions. Tissue sections were then briefly incubated in PBS and mounted with 25% glycerol/PBS.
Transient transfections. The plasmids used in the cotransfection assays include the expression vectors pCMV-p65/RelA (p65/RelA, under the control of the cytomegalovirus promoter) and pMSV-C/EBPa and pMSV-C/EBP-/3 (C/EBP-a and -/3 genes with the murine sarcoma virus long terminal repeat promoter) (16, 32) . Reporter vectors include SRE-luc, containing four copies of the c-fos promoter SRE sequence (-320 competition EMSA using regenerating liver nuclear extract from 0.5 h after hepatectomy (C/EBP) or 0 h (OE3) incubated with excess unlabeled oligonucleotide before the addition of labeled probe. (B) C/EBP binding in nuclear extracts prepared from regenerating liver at indicated times after hepatectomy. For clarity, the positions of the C/EBP isoforms as determined in Fig. 3 (Fig. 1 A) or C/EBP/3 ( Fig. 1 B) specific antibodies. The 42-and 30-kD bands detected represent alternative translation products of C/ EBPa that have different transcription activation functions (21, 45) . "LWP" represents an alternative translation product of C/ EBPB (25) . As surgery itself may induce a stress or acute phase response that could modify the level of nuclear proteins, we demonstrated that sham surgery has little effect on the levels of C/EBPa and C/EBP/3 protein levels during the time period when posthepatectomy changes in C/EBPa and C/EBPB levels are most pronounced (Fig. 1 C) .
The level of protein expression was determined using densitometric scanning of several immunoblots probed with C/EBPa or C/EBP3 antibodies (Fig. 1 D) . We did not observe any difference in the relative expression of the two isoforms of C/ EBPa or /3; thus, graphic representation of protein level is
shown only for C/EBPa (42 kD) and C/EBP,/ (36 kD). Although in Fig. 1 (Fig. 2 A) . The (Fig. 2 B) . We found that total DNA binding activity to the C/EBP consensus oligonucleotide remains relatively constant during the posthepatectomy period examined.
Relative CIEBPa and C/EBP/3 binding activities in regenerating liver nuclear extracts. To determine the relative contributions of C/EBPa and /3 to the binding activity at various times after hepatectomy, DNA binding complexes from normal liver 3, 16, 24, and 120 h after hepatectomy were incubated with an equal mixture of C/EBPa antibodies (a-N; a-14, a-C103; a-C104, a-C106) or a-C/EBPP (Fig. 3, A and B, indicated by the symbol a or /3 above the corresponding lanes). These times were chosen because they represent normal liver (0); early GI (3 h), when the level of / is increased relative to a; late GI (16 h) when the relative changes in C/EBP levels are maximal; S phase (24 h), when the level of P is still somewhat elevated; and after proliferation (120 h) when the level of a has renormalized. The addition of a-C/EBPa to the binding complex results in disruption of the upper portion of the binding complex at each time point examined. Addition of C/EBP/ antibody to the binding complex results in the formation of a band with decreased mobility (Fig. 3, arrows) and concomitant disappearance of the upper and lower portions of the binding complex. Taken together, the results of these supershift analyses suggest that the supershifted band that results from the addition of a-C/EBP/3 likely contains C/EBP/3 homodimer and C/EBPa/# heterodimer binding activity. The residual band that is not supershifted by a-C/EBP/3 most likely contains C/EBPa binding activity. Similarly, the disruption of the upper portions of the DNA binding complex by the addition of a-C/EBPa suggests that these complexes contain C/EBPa/ /3 heterodimer and C/EBPa homodimer binding activity. The remaining nondisrupted complex most likely contains C/EBPB homodimer binding activity. We cannot exclude the presence of other proteins in these bands, such as C/EBP6, because our C/EBP6 antibody was less effective in immunoblot and supershift studies. However, there appears to be relatively little contribution from homodimers other than C/EBPa and /3 be- cause there is virtually no activity that is unshifted by either a or P specific antisera.
There is a notable increase in the contribution of C/EBP/3 to the DNA binding complex, particularly when a comparison is made between 0 and 16 h after hepatectomy (see white arrows in lanes 11 and 12 in Fig. 3 A, and lanes 10 and 12 in Fig. 3  B) . There is a smaller decrease in the C/EBPa complex at 3 and 16 h (Fig. 3 B, (Fig. 4 A) . In that study, no comparison was made between the activity of C/EBPa and ,/.
We used F9 cells which have a low level of all of the transcription factors tested (16) and therefore provide a clean background in which to test the relative transactivation potential of individual factors. As shown, both C/EBPa and / strongly transactivate the promoter, although C/EBP,6 is more effective at lower concentrations. In regenerating liver, an NF-KB complex designated PHF/ NF-KB which contains p65/RelA and p5O/NF-KB1 is rapidly activated at 30 min after partial hepatectomy, a temporal course that is compatible with c-fos gene activation (13, 40) . Therefore, c-fos is a potential target gene of PHF/NF-KB. Previously it has been shown that p65/RelA acts synergistically with C/ EBP/3 to transactivate the SRE element (16) . As C/EBPs and NF-KB are simultaneously present in the early phases of liver regeneration, we assessed their combined impact on the SRE. Although both interact synergistically with p65/RelA, C/EBP/3 interacts more effectively than C/EBPa (Fig. 4 B) .
As C/EBPs are found in hepatocytes in regenerating liver, we reasoned that they might participate in transactivating hepatocyte-specific immediate-early genes. IGFBP-1 is a liver-restricted immediate-early gene that is transcriptionally activated in regenerating liver at 0.5-2 h after hepatectomy when the levels of C/EBPa have not yet fallen (51) . The IGFBP-J promoter is more effectively transactivated by C/EBPa (Fig. 4 C) than /3, which has virtually no activity. These studies provide initial support for the hypothesis that changes in the relative ratios of C/EBPa and 6 may result in differential target gene activation during liver regeneration. Markersfor normal liver, GJ and S phase in liver regeneration. Virtually all hepatocytes undergo proliferation after partial hepatectomy, but the timing of DNA synthesis varies in different zones (1) . We reasoned that one mechanism by which growth and differentiation could occur simultaneously in the regenerating liver would be if differentiated function were maintained at some times during the cell cycle and not others. If this were true, we would expect to see a mutually exclusive zonal distribution of proteins that are markers for growth and differentiation, respectively. Such distribution can be assessed by performing immunohistochemistry.
As a marker for hepatocytes, and for the integrity of the fixed sections, we demonstrated that albumin is detected throughout the liver before and after hepatectomy (Fig. 5 A) . The immediate-early gene, c-jun is a marker for early GI phase. We showed that c-Jun protein is present in the nuclei of hepatocytes throughout the liver at 3 h after hepatectomy (Fig. 5 B) . There is no zonal distribution of the protein, no expression in normal liver, and the induction at 3 h indicates that the liver in this sample is appropriately regenerating.
We used two markers for S phase, PCNA, an S phasespecific protein, and anti-BrdU antibody, to detect cells specifically synthesizing DNA in animals that had been pulsed for 1 h with BrdU. We found that PCNA is expressed in a large percentage of cells at 24 h after hepatectomy (Fig. 5 C) , and BrdU, a more specific indicator of DNA synthesis, is expressed at a high level in the periportal and lower level in the pericentral regions of the liver (Fig. 5 D) . These findings confirm that many hepatocytes have entered S phase of the cell cycle at 24 h after hepatectomy, the peak of the first round of DNA synthesis. The expected periportal increase in DNA synthesis is observed. a-C/EBPa Figure 6 . C/EBPa protein is found in virtually all hepatocyte nuclei in normal and regenerating liver. Livers were fixed as described in Methods. 5-jim tissue sections from the indicated times after hepatectomy were incubated with a C/EBPa specific antibody (a-C103) and antibody binding was detected using an avidin biotin horseradish peroxidase method. Portal vein and central vein regions are shown in the left and right panels, respectively. Identical exposure times, x62.5.
C/EBPa and C/EBPI3 expression in all hepatocytes throughout the temporal course of liver regeneration. Using a C/EBPa specific antibody, we were able to detect hepatocyte nuclear staining in normal and regenerating liver at 0, 3, 16, 24, and 120 h after hepatectomy (Fig. 6) . We found that virtually all hepatocyte nuclei are positive for C/EBPa at all time points examined and this staining is distributed equally throughout the liver parenchyma without any zonal localization to periportal or pericentral areas. There is no obvious difference in the absolute level of C/EBPa at any time after hepatectomy, but immunohistochemistry may not be the best method for quantitation. Our ability to detect C/EBPa in all hepatocyte nuclei in 3-h a-C/EBPO Figure 7 . C/EBP,3 protein is found in hepatocyte nuclei in normal liver and in regenerating liver 24 h after hepatectomy. Liver sections were prepared as described previously. Tissue sections from normal liver and 24 h after hepatectomy were incubated with a C/EBP/3 specific antibody and antibody staining was detected using the avidin biotin horseradish peroxidase method. Portal vein and central vein regions are shown in the left and right panels, respectively, X62.5.
posthepatectomy liver indicates that C/EBPa and c-Jun are coexpressed. Moreover, these findings suggest that C/EBPa expression coexists with DNA synthesis, but this fact was more firmly established by double labeling technology (see below).
Using an antibody to the C/EBP/3 protein, we detected nuclear staining in hepatocyte nuclei in normal liver and 24 h after hepatectomy (Fig. 7) . Nuclear staining appeared somewhat increased in the 24-h posthepatectomy liver as compared with normal liver. In addition, cytoplasmic staining is observed in the normal and regenerating liver, but as this antibody is not as effective for immunohistochemistry as the C/EBPa antibody, we do not know if the cytoplasmic staining is specific. As is the case for C/EBPa, there is no zonal pattern of nuclear staining. Because the C/EBPa and / antibodies used detect both isoforms of each protein, we cannot rule out region-specific differences in the levels of the different C/EBPa and /3 isoforms.
Continued expression of C/EBPa and /3 in hepatocytes that are synthesizing DNA. As a result of our observation that Cl EBPa and / proteins are expressed in the majority of hepatocytes throughout the posthepatectomy period, it seemed probable that these proteins are expressed in proliferating hepatocytes. To confirm that C/EBPa and 6 are expressed in hepatocytes which are in S phase of the cell cycle, we next performed double labeling studies in which C/EBPa (Fig. 8 A) or C/EBPP (Fig.   8 B) expression is colocalized with BrdU incorporation. We found that virtually all hepatocytes are positively stained for C/ EBPa or P in normal and 24-h posthepatectomy liver, which is consistent with our results with single labeling studies (Fig.  8, A and B, left panels) . Less (Fig. 8, arrows) . These results suggest that C/EBPa and P proteins continue to be expressed in hepatocytes that are in S phase of the cell cycle.
Discussion
This study is a complete and informative analysis of C/EBP expression in the context of liver regeneration that (a) uses immunoblot and DNA binding assays to provide accurate and consistent quantitation of C/EBPa and , / levels throughout the temporal course of liver regeneration and sham surgery; (b) assesses the relative impact of the C/EBP isoforms on expression of two regeneration-induced immediate-early genes; and (c) demonstrates the regional localization of C/EBP isoforms and their coexpression with markers of proliferation. The relative increase in C/EBP/3 to a in the prereplicative phase of liver regeneration may have a significant impact on target gene activation that may help promote liver growth. Our conclusion that substantial levels of C/EBPa and /3 isoforms are compatible with DNA synthesis in regenerating hepatocytes predicts that C/EBPs do not have profound growth inhibitory roles in this cell type.
We see no changes in the relative ratios of the C/EBPa (42 and 30 kD) or C/EBPP (36 and 20 kD) isoforms, which may be significant because different transactivation properties have been attributed to the various translational products (21, 25, 45) . In preadipocytes, the 42- C/EBPa message is antiproliferative, whereas the 30-kD alternative translation product is not antimitotic (21) ; it has been hypothesized that changes in the ratio of these two forms during rat liver development may regulate the balance between growth and differentiation. Either the liver is refractory to this antiproliferative effect of C/EBPa or the decline in C/EBPa expression seen in mid to late G1 and S phase is sufficient to permit entry into S phase.
The pattern of C/EBPB expression after partial hepatectomy suggests that C/EBPB is not likely to function as an antiproliferative factor in our model. Nuclear C/EBPB including active DNA binding C/EBPP is present throughout the early posthepatectomy period at levels that are consistently above prehepatectomy values. Like C/EBPa, C/EBP,/ is detected in hepatocytes that are in S phase of the cell cycle. A potential caveat of this study is that the phosphorylation state of C/EBP/3 may be important in determining its activity (54) , but currently there is no reason to suspect that phosphorylation of nuclear C/EBP/ controls C/EBPB activity during regeneration. Our findings contrast with a study (33) in which overexpression of LAP, the C/EBPP rat homologue, prevents the progression of HepG2 cells from GI to S phase. However, studies in isolated hepatocytes suggest that C/EBP/3 expression is compatible with DNA synthesis (55) , and it is known that hepatoma cells can exhibit different growth characteristics than hepatocytes. For example, hepatocyte growth factor inhibits hepatoma cell proliferation (56) but is stimulatory to hepatocytes (57-59). It is not surprising that C/EBPB expression blocks proliferation in a transformed cell line and is compatible with proliferation of hepatocytes in the regenerating liver.
Although C/EBPa levels drop abruptly in culture (55) , in association with the disappearance of most hepatocyte-specific gene expression this observation differs from that seen in the intact liver. These contrasting observations may reflect a requirement for matrix communications to maintain the differentiated phenotype. When isolated primary hepatocytes are cultured on a reconstituted basement membrane gel matrix, C/EBPa expression is restored (55) .
The absolute changes in the levels of C/EBPa and 3 are small but result in a more significant change of more than CYP2DS, ornithine transcarbamylase, and the al-acid glycoproteins genes have been shown to be differentially regulated by C/EBPa and P (16, (48) (49) (50) . Our initial studies of immediate-early promoters extend these observations because we found differential activation by the two C/EBP isoforms of both the fos SRE and the liver-specific IGFBP-J gene promoter. In fact, an interesting outcome of our studies is the implication that cfos gene expression may be controlled during liver regeneration by a cooperative interaction between a growth-induced transcription factor (PHF/NF-KB) and a liver-specific factor (C/ EBP), thus not necessarily requiring serum response factor, a known upregulator of c-fos during cell growth (60) . It will be important to examine the interactions between the C/EBP proteins and other growth-induced transcription factors that are likely to participate in the regulation of a variety of genes associated with maintenance of the differentiated state of the liver. For example C/EBPa and HNF-l via direct binding to the albumin promoter can synergistically activate the albumin gene in HeLa cells (18) . C/EBP proteins may also participate in the regulation of liver-specific immediate-early genes through interactions with growth-induced transcription factors. As shown above, C/EBPs may interact with NF-KB. Cooperative interactions have also been identified between C/EBP and activator protein-i transcription factors (61) , which are induced during liver regeneration (40) . Our ability to demonstrate C/ EBP, NF-KB (13, 14) , and c-Jun coexpression in regenerating hepatocytes provides a basis for examining potential interactions between these factors.
Possible targets for cooperative regulatory interactions are genes encoding gluconeogenic enzymes that are rapidly upregulated both at birth and in the remnant liver immediately after hepatectomy (4, 5, 61) . These include G6Pase, PEPCK, and potentially others, although currently only PEPCK is known to be regulated by C/EBP isoforms. C/EBP levels are low in tyrosinemic animals that show blunted induction of gluconeogenic enzymes at birth (62) . Animals in which both C/EBPa alleles have been deleted die within several hours of birth as a result of profound hypoglycemia and also show blunted induction of mRNAs encoding key gluconeogenic enzymes including G6Pase and PEPCK (63) . Thus, the expression of these genes correlates with C/EBP levels, suggesting that C/EBPs coupled with hormonal changes (64) may contribute in helping the liver to maintain glucose homeostasis during the acute stress of birth and removal of two-thirds of the liver. The persistence of C/ EBP expression during the major proliferative states of the liver during postnatal growth and hepatic regeneration suggests that differentiation-specific processes can cooperate with proliferation to support survival of the animal in these physiologic condi- 
